163 related articles for article (PubMed ID: 16037098)
1. Identification of CD36 molecular features required for its in vitro angiostatic activity.
Primo L; Ferrandi C; Roca C; Marchiò S; di Blasio L; Alessio M; Bussolino F
FASEB J; 2005 Oct; 19(12):1713-5. PubMed ID: 16037098
[TBL] [Abstract][Full Text] [Related]
2. Shear stress modulates the expression of thrombospondin-1 and CD36 in endothelial cells in vitro and during shear stress-induced angiogenesis in vivo.
Bongrazio M; Da Silva-Azevedo L; Bergmann EC; Baum O; Hinz B; Pries AR; Zakrzewicz A
Int J Immunopathol Pharmacol; 2006; 19(1):35-48. PubMed ID: 16569344
[TBL] [Abstract][Full Text] [Related]
3. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
4. Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2.
Xiao D; Li M; Herman-Antosiewicz A; Antosiewicz J; Xiao H; Lew KL; Zeng Y; Marynowski SW; Singh SV
Nutr Cancer; 2006; 55(1):94-107. PubMed ID: 16965246
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.
Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L
Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
Benndorf R; Böger RH; Ergün S; Steenpass A; Wieland T
Circ Res; 2003 Sep; 93(5):438-47. PubMed ID: 12881481
[TBL] [Abstract][Full Text] [Related]
8. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.
Simantov R; Febbraio M; Silverstein RL
Matrix Biol; 2005 Feb; 24(1):27-34. PubMed ID: 15748999
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells.
Chu LY; Ramakrishnan DP; Silverstein RL
Blood; 2013 Sep; 122(10):1822-32. PubMed ID: 23896411
[TBL] [Abstract][Full Text] [Related]
10. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.
Kazerounian S; Duquette M; Reyes MA; Lawler JT; Song K; Perruzzi C; Primo L; Khosravi-Far R; Bussolino F; Rabinovitz I; Lawler J
Blood; 2011 Apr; 117(17):4658-66. PubMed ID: 21378271
[TBL] [Abstract][Full Text] [Related]
11. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
12. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
13. Molecular mediators of angiogenesis in bladder cancer.
Campbell SC; Volpert OV; Ivanovich M; Bouck NP
Cancer Res; 1998 Mar; 58(6):1298-304. PubMed ID: 9515819
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1.
Nunes SS; Outeiro-Bernstein MA; Juliano L; Vardiero F; Nader HB; Woods A; Legrand C; Morandi V
J Cell Physiol; 2008 Mar; 214(3):828-37. PubMed ID: 17879962
[TBL] [Abstract][Full Text] [Related]
15. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
16. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
Weigand M; Hantel P; Kreienberg R; Waltenberger J
Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
[TBL] [Abstract][Full Text] [Related]
17. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF.
Dardik R; Inbal A
Exp Cell Res; 2006 Oct; 312(16):2973-82. PubMed ID: 16914140
[TBL] [Abstract][Full Text] [Related]
18. Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling.
Anderson CR; Hastings NE; Blackman BR; Price RJ
Am J Pathol; 2008 Oct; 173(4):1220-8. PubMed ID: 18772338
[TBL] [Abstract][Full Text] [Related]
19. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly.
Cezar-de-Mello PF; Nascimento-Silva V; Villela CG; Fierro IM
Oncogene; 2006 Jan; 25(1):122-9. PubMed ID: 16132039
[TBL] [Abstract][Full Text] [Related]
20. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
